Notice Regarding Change in Concurrent Positions of Directors
Astena HD announces changes to the concurrent positions of directors at its consolidated subsidiary, Iwaki Pharmaceutical Sakura Factory Co., Ltd.
📋 Article Processing Timeline
- 📰 Published: April 1, 2026 at 03:30
Astena Holdings Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President and Representative Director: Tomo Setoguchi; Securities Code: 8095) hereby announces that its consolidated subsidiary, Iwaki Pharmaceutical Sakura Factory Co., Ltd. (Headquarters: Sakura City, Chiba Prefecture; President and Representative Director: Takashi Hirose), resolved the concurrent positions of its directors at today's extraordinary general meeting of shareholders. Details are as follows.
Change in Concurrent Positions of Directors (Effective April 1, 2026)
(Note) The individual is scheduled to assume the position of Representative Director and Chairman at the Board of Directors meeting scheduled to be held on April 1, 2026, at Iwaki Pharmaceutical Sakura Factory Co., Ltd.
Astena Holdings Co., Ltd. Company Profile
Company Name: Astena Holdings Co., Ltd.
Location: 4-8-2 Nihonbashi Honcho, Chuo-ku, Tokyo
Representative: Tomo Setoguchi, President and Representative Director
Founded: July 10, 1914 (Taisho 3)
Established: September 20, 1941 (Showa 16)
URL: https://www.astena-hd.com/
Business Activities: Management of group companies, etc.
【Contact Information】
Astena Holdings Co., Ltd. Inquiry Form
https://www.astena-hd.com/contact/
FAQ
When will the change in the director's concurrent positions become effective?
It will be effective from April 1, 2026.
What is the background of this change in concurrent positions?
This is a resolution regarding the concurrent positions of directors at Iwaki Pharmaceutical Sakura Factory Co., Ltd. The detailed background has not been disclosed.
What are the business activities of Astena Holdings Co., Ltd.?
We are engaged in the management of group companies, etc.